• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Naturally occurring or recombinant proteins that are essentially free of large aggregates, particularly muteins (mutants) of porcine uric acid oxidase (uricase), may be used in the polymer so that the bioactivity of the protein remains essentially within the conjugate. Conjugation with a sufficiently small number of strands can result in substantially non-immunogenicity. Such conjugates are particularly well suited for the treatment of chronic symptoms because they cause less antibody formation and / or accelerated clearance than similar conjugates prepared from protein preparations containing trace amounts of large aggregates. same.
    公开号:KR20020087934A
    申请号:KR1020027010189
    申请日:2001-02-07
    公开日:2002-11-23
    发明作者:메리 알. 셔먼；마아크 지. 피. 사이퍼；엘. 데이비드 윌리엄스
    申请人:마운틴 뷰 파마슈티컬즈 인크.；
    IPC主号:
    专利说明:

    AGAGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES}
    [3] Field of invention
    [4] The present invention relates to the purification and chemical modification of proteins to extend their circulating life and to reduce their immunogenicity. More specifically, the present invention relates to Urate Oxidase (Uricase) before conjugation of poly (ethylene glycol) or poly (ethylene oxide). uricase) from the aggregates larger than octamers. This substantially eliminates its immunogenicity without compromising uricase's uric acid degradation activity.
    [5] Technology in related fields
    [6] The statements contained in this background are not an admission of prior art, but rather reflect the inventor's own subjective comment and interpretation of the state of the art at the time the invention is made. These interpretations are private and may include the insights of inventors that have not been published so far, and such insights themselves are not part of the prior art.
    [7] Uric oxidases (uricases; EC1.7.3.3) are enzymes that catalyze the oxidation of uric acid to more soluble products, allantoin, a more readily secreted purine metabolite. Humans do not produce enzymatically active uricases as a result of several mutations in the gene for our kinases obtained during the evolution into higher primates. Wu, X all, (1992), J. Mol. Evol 34: 78-84. Thus, in sensitive people, the presence of excess concentrations of uric acid in the blood (hyperuricemia) and the presence of excess concentrations of uric acid in the urine (hyperuriasuemia: hyperuricosuria) are associated with painful arthritis (gout), imbalance. May cause urate deposition (gout nodules) and nephritis. In some infected patients, commercially available drugs, such as allopurinol (an uric acid inhibitor), may result in treatment-limiting side effects or fail to adequately treat these symptoms. Hande, KR, Ildong., (1984) Am J. Med. 76: 47-56; Fam, AG, (1990) Bailliere's Clin Rheumatol 4: 177-192. Injecting uricase can, at least temporarily, relieve hyperuricemia and hypouricemia. However, we Carr agent to man because heterologous protein, Aspergillus Plastic booth even primary injection of the unmodified protein from (Aspergillus flavus), causes an anaphylactic type reaction (anaphylactic reaction) In a few percent of the treated patients (Pui, CH group, (1997) Leukemia 11: 1813-1816), and also immunological responses limit its utility for long-term or intermittent treatment. Donadio, D. et al. (1981) Nouv Press Med 10: 711-712; Leaustic, M. group, (1983) Rev. Rhum Mal Osteoartic 50: 553-554.
    [8] United States Patent Application No. 09 / 370,084 and published International Application PCT / US99 / 17514 disclose poly (ethylene) having substantially reduced immunogenicity while retaining at least about 75% of the uricase activity of unconjugated uricases. Glycol) -urinate oxidase (PEG-uricase). In one such purified uricase, each subunit is covalently bound to an average of 2 to 10 strands of PEG, wherein each molecule of PEG has a molecular weight between about 5 kDa and 100 kDa Can have
    [9] Aggregation of proteins is known to increase their immunogenicity. This understanding is intended to intentionally aggregate proteins, or antisera, by exposure to glutaraldehyde to form cross-linking or by treatment such as thermal denaturation prior to use in the manufacture of vaccines. Contributed to the development of a method of immunizing an animal to prepare it.
    [10] Unintentional aggregation of proteins can also be used in therapeutic proteins such as human gamma glubulin (Henney et al. (1968) N. Engl. J. Med. 278: 2244-2246) and human growth hormone ( human growth hormone (Moore et al. (1980) J. Clin. Endocrinol. Metab . 51: 691-697) is recognized to contribute to immunization or sensitization during clinical use. The contribution of aggregates to immunogenicity of human interferon alpha has been shown in BALB / c mice (Braun et al. (1997) Pharm. Res. 14: 1472-1478), and enzyme-linked immunosorbent assay (ELISA: enzyme-linked) An immunosorbent assay was developed for their measurement (Braun et al. (1997) Pharm. Res. 14: 1394-1400).
    [11] In contrast to the known effects of aggregation on the immunogenicity of proteins, there are no reports of the effects of aggregation on the immunogenicity of proteins conjugated to poly (alkylene glycols) such as PEG. There is a need for poly (alkylene glycol) -uricase conjugates that substantially eliminate the immunogenicity of uricase without reducing uric acid degradation activity. The present invention provides such a composition.
    [1] Statement of Government Rights in the Invention
    [2] Some of the studies described in this application were supported by the U.S.-Israel Binational Industrial Research and Development Foundation. Thus, the United States Government may have certain rights in this invention.
    [12] Summary of the Invention
    [13] Conjugation of proteins with poly (alkylene glycols), in particular PEG, results in conjugates with reduced immunogenicity and increased persistence in the bloodstream. In the intention of preparing conjugates of uricase that are substantially non-immunogenic with retaining almost all of the uricase activity of the unmodified uricase agent, the presence of trace amounts of large aggregates of uricase in the starting material It has been found to be surprisingly effective in causing both the formation of the antibody and the accelerated clearance from circulation, wherein both the formation of the antibody and the accelerated clearance from the circulation are PEG conjugates made from uricases containing such aggregates. What happens after repeated scanning of the gate is harmful. Surprisingly, the inventors have found that increased immunogenicity and accelerated clearance are greater than natural tetramers, ie aggregates of well-defined, medium-size uricase subunits (eg, aggregates containing eight subunits (8). Not due to the presence of the polymers). The octameric form of uricase can be detected by its UV light absorption (such as at 214 nm or 276 nm) or by other measurements on protein concentration or its contribution to refractive index, so that the concentration is high enough in most uricase formulations. Exists as. Nevertheless, in contrast to the much smaller amounts of much larger aggregates which cannot be detected by UV absorption under the conditions tested but are soon detected by static or dynamic light scattering. As a result, octamers themselves have been found to contribute minimally to immunogenicity and accelerated elimination of PEG-uricase conjugates. Thus, it has been found that removing such traces of very large aggregates prior to conjugation with PEG surprisingly reduces the immunogenicity and accelerated elimination of the resulting PEG-uricase conjugates.
    [14] One embodiment of the present invention is purified uric acid oxidase (uricase) with little aggregates greater than octamer. Preferably, the uricase is a mammalian uricase. More preferably, the uricase is swine liver, bovine liver or sheep liver uricase. In one aspect of this preferred embodiment, the uricase is a recombinant. In another aspect of the present preferred embodiment, the uricase has substantially the sequence of pig, bovine, sheep or baboon uricase. Advantageously, the uricase is chimeric. Preferably, the uricase is PKS uricase. In another aspect of the present preferred embodiment, the uricase has substantially the sequence of non-liver liver uricase in which tyrosine No. 97 is substituted with histidine. Preferably, the uricase comprises an amino terminus and a carboxy terminus, wherein the uricase is truncated at one or both ends. Advantageously, the uricase is a fungal or microbial uricase. Preferably, the fungus or microbial uricase is isolated from Aspergillus flavus, Arthrobacter globiformis, Bacillus sp. Or Candida utilis, or Or a recombinant enzyme having substantially one sequence of the uricase. Alternatively, the uricase is an invertebrate uricase. Preferably, the invertebrate uricase is a recombinant enzyme isolated from Drosophila melanogaster or Drosophila pseudoobscura or substantially having the sequence of one of the uricases. . In another aspect of the present preferred embodiment, the uricase is a plant uricase. Preferably, the plant uricase is a recombinant enzyme isolated from the root nodule of Glycine max or having substantially the sequence of the uricase.
    [15] In one aspect of this preferred embodiment, the uricases described above are conjugated to poly (ethylene glycol) or poly (ethylene oxide) under conditions where the uricase in the conjugate is substantially free of aggregates greater than octamers. . Preferably, the uricase is conjugated to a poly (ethylene glycol) or poly (ethylene oxide) via a urethane (carbamate), secondary amine or amide bond. In one aspect of the present preferred embodiment, the poly (ethylene glycol) is monomethoxy poly (ethylene glycol). In another aspect of this preferred embodiment, the poly (ethylene glycol) or poly (ethylene oxide) has a molecular weight between about 5 kDa and 30 kDa. Preferably, the poly (ethylene glycol) or poly (ethylene oxide) has a molecular weight between about 10 kDa and 20 kDa. Advantageously, the average strand number of the poly (ethylene glycol) or poly (ethylene oxide) is between about 2 and 12 strands per uricase subunit. More advantageously, the average number of strands of the poly (ethylene glycol) or poly (ethylene oxide) is between about 6 and 10 per uricase subunit. Most advantageously, the average number of strands of the poly (ethylene glycol) or poly (ethylene oxide) is between about 7 and 9 per uricase subunit. Preferably, the poly (ethylene glycol) or poly (ethylene oxide) is linear. Alternatively, poly (ethylene glycol) or poly (ethylene oxide) is branched.
    [16] The present invention also provides a pharmaceutical composition for lowering the level of uric acid in a bodily fluid or tissue, the composition comprising the uricase described above and a pharmaceutically acceptable carrier. Preferably, the composition is stabilized by lyophilization and dissolved by reconstitution to provide a suitable solution for parenteral administration.
    [17] Another embodiment of the present invention is a method for purifying uricases with reduced immunogenicity, which separates uricase aggregates larger than 8 mers in uricase fractions and separates the aggregates from purified uricases. Exclusion. Preferably, the separating step comprises detecting aggregates larger than octamer from at least some of the uricase fractions and excluding fractions containing the aggregates. Advantageously, said detecting step comprises the measurement of light scattering.
    [18] The present invention also provides an isolated uricase prepared by the process described above.
    [19] Brief description of the drawings
    [20] FIG. 1 shows our casease activity, total protein and salt concentrations in fractions from Pharmacia Biotech Mono Q (1 × 10 cm) anion exchange column. Uricase activity was measured by monitoring the reduction in absorption at 292 nm of 100 μM uric acid in 200 mM sodium borate, pH 9.2, at room temperature. Total protein was determined from the area under the absorption peak curve of ourcase in size-exclusion HPLC analysis.
    [21] FIG. 2 shows selected fractions and loads from preparative mono Q chromatography of swine uricase containing R291K and T301S (PKS uricase) mutations on a Pharmacia Superdex 200 column (1 × 30 cm). Shown the size-exclusion HPLC analysis, the data obtained by light scattering detector at 90 ° C. (upper curve) and by absorption at 276 nm (lower curve) are shown. Different signal intensities of tetramers, octamers and higher aggregated uricase forms in unfractionated samples (loads) and various fractions are evident. The load was diluted to 1/5 with mono Q column buffer, fraction 5 to 1/3, and fraction 6 to 1/9. Fractions 5 and 6 combined to form a "low salt pool".
    [22] FIG. 3 shows a size-exclusion analysis of fractions from the mono Q column of FIG. 1, showing data obtained by absorption at 276 nm and light scattering detector at 90 °, as in FIG. 2. Fractions shown in this figure were used to form a "high salt pool" from which PEG conjugates were prepared and injected into BALB / c mice. Results Immunogenic responses and serum activity in BALB / c mice are shown in FIGS. 5 and 6.
    [23] FIG. 4 shows light scattering at 90 ° calculated from the data of FIGS. 2 and 3 of selected fractions (FIG. 1) and unfractionated PKS Uricase from preparative mono Q column chromatography of PKS Uricase. And octameric content determined by absorption at 276 nm.
    [24] FIG. 5 shows incubations at 37 ° C. for 4 hours in serum extracted 24 hours after 6 weeks of weekly injection with 6 × 10-kDa PEG conjugates of pools from PKS uricase or mono Q column fractions. UV activity as shown in FIG. 1 for the casein activity is shown.
    [25] FIG. 6 shows mono-Q shown in FIG. 1 in PEG conjugates of PKS uricase, and in serum drawn 24 hr after weekly injections into female BALB / c mice for 6 weeks with 0.2 mg of uricase protein per 20 g body weight. ELISA analysis of IgG antibody formation against PEG conjugates of the pool of fractions from the column is shown. For each mouse, data from bleeding 24 hours after the first to sixth injection is shown from left to right. Assay conditions are described in Example 6. Data for 8 mice in each group are arranged from left to right in order of increasing immune response.
    [26] Detailed description of the preferred embodiment
    [27] Previous studies have shown that when conjugation with PEG (PEGylation) results in a significant decrease in the immunogenicity and / or antigenicity of the uricase, it necessarily involves a significant decrease in uric acid degradation activity. The present invention includes the observation that trace amounts of urate oxidase aggregates larger than octamers substantially contribute to the induction of immunogenicity and accelerated clearance of PEG-uricase conjugates. This finding seems to apply to most other proteins, including interferon and growth factors, in addition to our case.
    [28] The safety, convenience and cost-effectiveness of biopharmaceuticals are all adversely affected by the reduction in their efficacy and the need to increase the resulting administered dose. Thus, there is a need for a safe and effective alternative to reducing elevated levels of uric acid in body fluids, including blood and urine. The present invention provides a method for producing uricase, which excludes uricase aggregates larger than octamers, for use in the synthesis of PEG-uricase. This PEG-uricase retains all or almost all of the urate degrading activity of the unmodified enzyme. The present invention also provides purified uricases that are substantially free of aggregates larger than octamers. The phrase “substantially free” indicates that the purified uricase contains up to about 2%, preferably up to about 1%, aggregates larger than the octamer.
    [29] The present invention provides a method for purifying uricase that allows for the aggregation of larger than octamers from the purified formulation. Because these larger aggregates are very immunogenic, their presence in purified uricase preparations is undesirable. Since aggregates may be too diluted to be detected by ultraviolet absorption, the method involves monitoring column fractions in addition to ultraviolet absorption at 280 nm, or by light scattering rather than ultraviolet absorption. The purified uricase is then conjugated to water-soluble polymers, preferably poly (ethylene glycol) or poly (ethylene oxide), as described in co-pending US patent application Ser. No. 09 / 370,084.
    [30] The removal of aggregated uricases from predominantly tetrameric uricase preparations involves centrifugation including size-exclusion chromatography, ion-exchange chromatography, ultrafiltration through microporous membranes, and ultracentrifugation. In addition, it can be achieved using methods known to those skilled in the art. Separation methods may include separation and analysis of fractions, and rejection, ie exclusion, of those fractions that contain large aggregates in excess. Results The uricase preparation is more suitable for the synthesis of uricase conjugates that are substantially non-immunogenic than uricase, which is not fractionated. For long term administration, it is important that PEG conjugates of proteins such as PEG-uricases, for example, have low immunogenicity and do not cause progressively faster clearance from the bloodstream even after repeated administrations.
    [31] The present invention also provides a pharmaceutical composition of the polymer-uricase conjugate. These conjugates are substantially non-immunogenic and retain at least 75%, preferably 85%, more preferably 95% or more of the uric acid activity of the unmodified enzyme. Uriases suitable for conjugation to water soluble polymers are mutated, hybridized, and / or naturally occurring uric oxidases isolated from bacteria, fungi (fungi), and tissues of plants and vertebrates and invertebrates. Or recombinants of uricase, including variants of truncated enzymatically active uricase. Water soluble polymers suitable for use in the present invention include both linear and branched poly (ethylene glycol) or poly (ethylene oxide), commonly known as PEG. Examples of branched PEGs are the subject of US Pat. No. 5,643,575. One preferred example of a linear PEG is a monomethoxy PEG of the general formula CH 3 O— (CH 2 CH 2 O) n H where n varies between about 100 and about 2,300.
    [32] One embodiment of the invention is a conjugate of uric acid oxidase (uricase) that retains at least about 75% of the uricase activity of the unconjugated uricase and has substantially reduced immunogenicity. Uricasease according to this aspect of the invention may be a recombinant. Whether recombinant or not, the uricase may be of mammalian origin. In one aspect of this embodiment, the uricase may be a uricase of pig, bovine or sheep liver. In another aspect of this embodiment, the uricase can be chimeric. The chimeric uricase may contain portions of swine liver and / or baboon liver uricase. For example, the chimeric uricase may be porcine uricase comprising the mutations R291K and T301S (PKS uricase). Alternatively, the uricase may be a non-liver liver uricase in which tyrosine No. 97 is substituted with histidine, thereby increasing the specific activity of our case by at least about 60%. The uricases of the invention may be in truncated form at the amino terminus, at the carboxyl terminus, or at both terminus, whatever their origin. Likewise, the uricase can be a fungal or microbial uricase. In one aspect of this embodiment, the fungus or microbial uricase is Aspergillus flavus, Arthrobacter globiformis, Bacillus sp. Or Candida utilis. It may be a naturally occurring form or a recombinant form of uricase from. Alternatively, the uricase can be an invertebrate uricase such as, for example, a naturally occurring or recombinant form of Drosophila melanogaster or Drosophila pseudoobscura uricase. have. The uricases of the present invention may also be plant uricases, such as naturally occurring or recombinant forms of uricase, for example from soybean root nodules ( Glycine max ). PEG can have an average molecular weight between about 5 kDa and 100 kDa; Preferably, PEG may have an average molecular weight between about 8 kDa and 60 kDa; More preferably, PEG may have an average molecular weight between about 10 kDa and about 40 kDa, such as, for example, 10-20 kDa. The covalently bound average number of strands of PEG can be from 2 to 12 strands per uricase subunit; Preferably, the average number of strands covalently bonded may be 6 to 10 per subunit; More preferably, the average number of strands of PEG can be 7 to 9 per subunit. In one aspect of this embodiment, the uricase may be tetramer. The strands of PEG can be covalently bound to urcasees via urethane (carbamate) bonds, secondary amine bonds and / or amide bonds. When the uricase is a recombinant form of any of the uriases mentioned herein, the recombinant form may have a sequence of substantially naturally occurring forms.
    [33] One preferred mammalian uricase is the recombinant swine-bee chimeric uriase, which consists of portions of the sequence of swine liver and baboon uricase, all of which are first described by Wu et al. (1989). It was decided. One example of such a chimeric uricase contains the first 288 amino acids from the swine sequence (SEQ ID NO: 1) and the last 16 amino acids from the non-SEQ ID NO (SEQ ID NO: 2). Hershfield, et al., International Publication WO 00/08196, Urate Oxidase, published February 17, 2000. The latter sequence differs only in two positions from the pig sequence (residue lysine (K) instead of arginine at residue 291, 301). In the position position serine (S) instead of threonine, this mutation is called pig-KS, or PKS uricase (SEQ ID NO: 3). Since PKS urasease has one more lysine residue, it has one more potential position for PEGylation than either the pig or baboon sequence.
    [34] CDNAs for various mammalian uricases, including PKS uricases, were subcloned and optimal conditions for expression in E. coli were determined using standard methods. Erlich, HA, (Ed.) (1989) PCR Technology, Principles and Applications for DNA Amplification. New York: Stockton Press; Sambrook, J, et al., (1989) Molecular Cloning. A Laboratory Manual, Second Edition. See Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. Recombinant uricases were extracted and purified and their stability and activity evaluated using modifications of standard assays. Fridovich, I (1965) J. Biol Chem 240: 2491-2494; Nishimura, et al. (1979), and Examples 1-5.
    [35] In one embodiment of the present invention, the uricase can be conjugated via a covalent bond that is biologically stable and nontoxic to a relatively small number of PEG strands. Such bonds may include urethane (carbamate) bonds, secondary amine bonds, and amide bonds. Various activated PEGs suitable for such conjugation are described in Huntsville, AL. Available from Shearwater Polymers, Inc.
    [36] For example, urethane bonds to uricase can be formed by culturing uricase in the presence of p-nitrophenyl carbonate (NPC) or succinimidyl carbonate (SC) derivatives of PEG. SC-PEG can be synthesized using the procedure described in US Pat. No. 5,612,460. NPC-PEG can be synthesized by reacting PEG with p-nitrophenyl chloroformate according to the methods described in Veronese, FM, et al., (1985) Appl Biochem Biotechnol 11: 141-152 and US Pat. No. 5,286,637. . The method described in the '637 patent is applied to PEG with higher molecular weight by adjusting the concentration of reactants to maintain similar stoichiometry. Another method of NPC-PEG synthesis is described in Buttner W. et al., West German patent specification DD 279 486 A1.
    [37] Amide linkages to uricases can be obtained using N-hydroxysuccinimide esters (Shearwater Polymers) of carboxylic acid derivatives of PEG. Secondary amine bonds may be used for reductive alkylation using 2,2,2-trifluoroethanesulfonyl PEG (tresyl PEG; Shearwater Polymers) or PEG aldehydes (Sohearwater Polymers) and sodium cyanoborohydride. Can be formed.
    [38] For conjugates containing PEG with a molecular weight of 10 kDa, the maximum number of strands of PEG bound per subunit while retaining at least 75% of the urate degrading activity of the unmodified enzyme is determined by mammalian uricase (e.g. About 12 strands for the mutein of the casein, porcine uricase; see assay conditions in Example 5. The degree of the latter PEGylation corresponds to about 40% of the total amino groups. In one embodiment of the invention, the average number of strands of PEG bound per uricase subunit is between about 2-12. In a preferred embodiment, the average number of strands of PEG bound per uricase subunit is between about 6 and 10. In a more preferred embodiment, the average number of covalently bound strands of PEG per uricase subunit is between about 7-9. In another embodiment, the molecular weight of PEG used for the binding reaction is between about 5 kDa and 30 kDa, preferably between about 10 kDa and 20 kDa.
    [39] There are several factors that can influence the choice of the appropriate molecular weight and number of strands of PEG to bind to a given form of our case. In general, reducing or eliminating immunogenicity without a significant loss of uric acid degradation activity may require a relatively high number of strand binding of lower molecular weight PEG compared to the relatively small number of strands of higher molecular weight PEG. . Likewise, each different form of uricase can have different titration conditions for both size and number of strands. The titrant strand number and PEG molecular weight of PEG can be determined immediately using the methods described herein.
    [40] When PEG conjugates of mammalian uricases were prepared from purified tetrameric and octameric forms of enzymes (including four or eight subunits of about 35 kDa), they contained large aggregates. In contrast to the moderate immunogenicity of the PEG conjugates of the casease formulations (see FIG. 6) and the very high immunogenicity of the unmodified enzymes, mice showed markedly reduced immunogenicity.
    [41] Purified formulations of naturally occurring and recombinant uricases generally comprise a mixture of very large enzyme aggregates with tetrameric (140-kDa) and octameric (280-kDa) forms. The percentage of each uricase preparation in tetrameric or octet form generally varies from about 20% to 95% (see Figures 2-4). Despite the evidence that non-PEGylated aggregates of several different proteins are highly immunogenic (see, eg, Moore, WV, et al., (1980) J. Clin. Endocrinol Metab 51: 691-697), PEG Previous studies on uricase did not describe any effort to limit the content of aggregates, indicating that the potential immunogenicity of PEG-modified aggregates was not considered. On the basis of the present observation, it is likely that such aggregates were present in the enzyme preparations used for the previous synthesis of PEG-uricases. Their presence seems to have made the task of making non-immunogenic conjugates even more difficult. It is also likely that the significant loss of uric acid activity observed in previous efforts to PEGylate uricases was associated with higher strand numbers of bound low molecular weight PEG. On the other hand, the PEGylation and uricase purification methods described herein include at least certain uricases such as PKS uricase (mutein of pig uricase ) and thermophilic Bacillus sp. For enzymes from, it allows for covalent binding to up to 12 strands of PEG per subunit, while retaining at least 75% of uric acid degradation activity.
    [42] In another preferred embodiment, substantially all large aggregates of the enzyme are ion-exchange chromatography at pH about 9 to 10.5, preferably 10.2, prior to conjugation of the resulting substantially aggregate-free uricase agent to PEG. It may be removed by chromatography (FIG. 1-3) or size-exclusion chromatography. The molecular weight of our case in each fraction from the preparative column is, for example, including HPLC, conventional size-exclusion chromatography, centrifugation, light scattering, gel electrophoresis or capillary electrophoresis in undenatured buffer. It can be monitored by any size-dependent analysis technique. For uricases without aggregates isolated using size-exclusion chromatography, fractions containing only enzymes between 140-kDa and 280-kDa can be collected and used for conjugation to PEG. For quaternary and octameric uricases isolated using ion-exchange chromatography, fractions from the ion-exchange column can produce significant amounts of tetrameric and octameric forms without the large aggregates in which any fraction is detected by light scattering. It can be analyzed for size to determine if it contains. Accordingly, large aggregates, which are undesirable for the purified product, may constitute a small amount or less than about 1% of the total uricase.
    [43] The results presented here indicate that even with severe PEGylation, PKS uricase forms larger than octamers result in accelerated clearance (FIG. 5) and are somewhat immunogenic in mice (FIG. 6). Conversely, conjugates prepared from uricases that were essentially free of large aggregates (which could be detected by light scattering) could be reinjected at least six times at weekly intervals with much lower evidence of accelerated clearance (FIG. 5). ), As determined by the sensitizing enzyme-linked immunoassay, there was no formation of detectable antibodies (FIG. 6). The use of highly purified tetramers or octamer uricases further distinguishes the improved conjugates of the present invention from the previously described PEG-uricase agents. Conversely, the presence of significant amounts of large aggregates in the uricase preparations used by some previous researchers has led to their binding to a large number of strands of PEG in their efforts to inhibit immunogenicity. As a result, the enzymatic activity of the resulting conjugates was significantly reduced.
    [44] The PEG-uricasease conjugates of the present invention are useful for lowering uric acid levels in tissues and body fluids of mammals, preferably humans, and are therefore useful for gout, tophi and renal insufficiency, organ transplantation ( It can be used for the treatment of elevated uric acid levels accompanying symptoms such as organ transplantaion and malignant diseases. PEG-uricase conjugates can be injected into mammals with excess uric acid levels by one of many routes including intravenous, subcutaneous, intradermal, intramuscular, and intraperitoneal routes. have. Alternatively, they can be nebulized and inhaled. Patton JS. (1996) Adv. Drug Delivery Rev. 19: 3-36 and US Pat. No. 5,458,135. Effective dosages of PEG-uricasees of the invention will depend on the level of uric acid and the size of the individual. In one embodiment of this aspect according to the invention, the PEG-uricase can be administered in a pharmaceutically acceptable excipient or diluent in an amount ranging from about 10 μg to about 1 g. In a preferred embodiment, the amount administered is between about 100 μg and 500 mg. More preferably, the conjugated uricase is administered in an amount between 1 mg and 100 mg, such as 5 mg, 20 mg, or 50 mg. Mass given for a dosage of embodiments refers to the amount of protein in the conjugate.
    [45] Pharmaceutical formulations containing PEG-uricases are described in the prior art, as described, for example, in Gennaro, AR. (Ed.) (1990) Remington's Pharmaceutical Sciences , 18th Edition Easton, PA: Mack Publishing Co. It can be manufactured by. Suitable excipients for the preparation of injectable solutions include, for example, phosphate buffered saline, lactated Ringer's solution, water, polyols and glycerol. Pharmaceutical compositions for parenteral injection include pharmaceutically acceptable sterile aqueous or non-aqueous liquids, dispersions, suspensions, or emulsions, and sterile powders for reconstitution just prior to use into sterile injectable solutions or dispersions. It is configured by. Such formulations may contain additional ingredients such as, for example, preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, buffers, antioxidants and diluents.
    [46] PEG-uricases may also be provided as controlled release compositions for implantation into an individual to continuously inhibit elevated uric acid levels in body fluids. For example, polylactic acid, polyglycolic acid, regenerated collagen, poly-L-lysine, sodium alginate, gellan gum, chitosan, agarose, multilamellar liposomes and many other conventional depots Depot agents include bioerodible or biodegradable materials that can be formulated with biologically active compositions. These substances, when implanted or injected, slowly disintegrate to release the active material into surrounding tissue. For example, one method of encapsulating PEG-uricases includes the method disclosed in US Pat. No. 5,653,974. Biocorrosion, biodegradability and the use of other depot agents have been widely considered in the present invention. The use of matrix entrapment systems and infusion pumps for the delivery of PEG-uricases is also within the scope of the present invention. PEG-uricases can also be usefully enclosed in micelles or liposomes. Liposomal encapsulation techniques are well known in the art. Lasic D. et al., (Eds.) (1995) Stealth Liposomes. See Boca Raton, FL: CRC Press.
    [47] PEG-uricasease pharmaceutical compositions of the invention are, for example, such as organ transplant recipients (see Venkataseshan, VS, et al., (1990) Nephron 56: 317-321) and patients with some malignant diseases. In addition, the need for hemodialysis will be reduced in patients at high risk for kidney disease induced by urate. In patients with high levels of crystalline urate (gout nodules), such pharmaceutical compositions will improve quality of life faster than currently available treatments.
    [48] The following embodiments, which are not intended to limit the invention in any sense, illustrate these various aspects. These examples describe PEG-uricases made by binding an activated PEG (eg, p-nitrophenyl carbonate derivative) to a mutein of porcine uricase. These examples provide substantially non-immunogenic uricase conjugates to those of ordinary skill in the art that retain at least about 75% of the uriculate activity of the unmodified enzyme and are well suited for long-term administration. Provide guidance for manufacturing.
    [49] Example 1
    [50] Ion-Exchange Chromatography for the Preparation of Uricase
    [51] Preparative ion-exchange chromatography was performed on a Fast Protein Liquid Chromatography (FPLC) device (Amersham Pharmacia, Piscataway, NJ.). Mono Q column (1 × 10 cm, Amersham Pharmacia) from 50 mM sodium carbonate, pH 10.3, 0.1 M NaCl (buffer A) to a gradient of 50 mM sodium carbonate, pH 10.3, 0.6 M NaCl (buffer B) Eluted at a flow rate of 0.5 ml / min and the sample was loaded at a lower flow rate. This technique was used to fractionate 25 mL of PKS uricase (pH 10.3) solution. PKS uricase was obtained from Bio-Technology General limited (Rehovot, Israel). The latter is a recombinant porcine uricase in which one lysine (K) residue and one serine (S) residue are replaced with one arginine residue and one threonine residue in the parental pig sequence (Lee et al. 1988) Science 239: 1288-1291; Wu et al. (1989) Proc. Natil. Acad. Sci. USA 86: 9412-9416). After the sample was loaded, the column was washed with 100 mL of Buffer A. Uricase peak began to elute at the end of 31 mL linear gradient of 0-26% buffer B. Most uricases were eluted isocratically with 7 mL of buffer containing 26% buffer B. The remainder of the recovered uricase was eluted by a linear 89-mL gradient of 26% to 100% Buffer B. Fractions of 4 mL or 6 mL were combined. Fractions # 4-11 were assayed for uricase and total protein (FIG. 1) and analyzed by size-exclusion high performance liquid chromatography (HPLC) as described in Example 2 ( 2 and 3). The remaining fractions of # 5-10 were bound to PEG, as described in Example 3. Based on the analysis results in Example 2, PEG conjugates of fractions # 5 and # 6 are combined as a "low-salt pool" and fractions # 7-10, as shown in FIG. Of their PEG-conjugates were combined as a "high-salt pool."
    [52] Example 2
    [53] Size-Exclusion Chromatography of Uricase Monitored by Light Scattering and Ultraviolet Absorption
    [54] Size-exclusion HPLC was performed on selected fractions from mono Q chromatography for preparation of unfractionated PKS Uriase and PKS Uriase of Example 1 on a Superdex 200 column (1 × 30 cm, Amersham Pharmacia Biotech) at room temperature. Was performed. Eluate from absorption monitor (UV 2000) by Thermo Separations HPLC (Sunnyvale, CA) was analyzed by light scattering at 90 ° to incident light using a MiniDawn detector from Wyatt Technologies (Santa barbara, CA). .
    [55] The results shown in FIGS. 2-4 show the resolution between tetramers, octets and larger aggregates of the uricase subunit and the different ratios of signals detected from these uricase forms in the various samples. Unlike the absorption signal, which is directly proportional to the concentration, the light scattering signal is proportional to the product of the light scattering unit times the concentration. The sensitivity of the light scattering detector to very small amounts of highly aggregated uricase revealed the presence of the largest aggregates, which eluted at or near the void volume (about 7 mL).
    [56] Example 3
    [57] Synthesis of PEG-uricasease Conjugates
    [58] P-nitrophenyl of PEG from unclassified PKS uricase (from Bio-Technology General Limited) and fractions from the mono Q column of Example 1 from Shearwater Polymers (Huntsville, AL.) Carbonate derivative (NPC-PEG) was used to bind to 10-kDa PEG. The preparation of NPC-PEG from PEG using phenylchloroformate has been described in several reports (eg Veronese, FM, et al., (1985) Appl. Biochem. Biotechnol. 11: 141-152; Kito, M. et al., (1996) J. Clin. Biochem Nutr. 21: 101-111) NPC-PEG has also been used in the synthesis of PEG-protein conjugates by previous researchers, including the present inventors ( For example, Veronese et al, supra ; Sherman, MR, et al., In JM Harris, et al., (Eds.) Poly (ethylene glycol) Chemistry and Biological Applications.ACS Symposium Series 680 (pp. 155-176 ) Washington, DC: American Chemical Society. The number of strands of 10-kDa PEG bound to each subunit of uricase is described in Kunitani, M. et al., (1991) J. Chromatogr. 588: Six (6) was determined by the method described in 125-137.
    [59] Example 4
    [60] Serum Persistence and Immunogenicity of Uricase and Uricase
    [61] PEG conjugates of recombinant mammalian uricase prepared according to the method of Example 3 were adjusted to 1 mg protein / mL in phosphate-buffered saline (PBS), pH 7.4, for injection. . Samples were frozen and stored until analysis or injection. Samples were heated to 37 ° C. within 1 hour before injection into groups of 8 BALB / c female mice. The group of mice had an average body weight in the range of 18-22 g at the beginning of the study.
    [62] Body weights of all mice were monitored and evidence of adverse reactions to injections or other evidence of poor health. 24 hours after six weekly injections, 100-200 μL of blood is removed except for anesthetizing animals with ketamine and sacrificing when collecting more blood (pulling). Pulled from the back. Serum was prepared from coagulated blood at 2-8 ° C. for 4 to 32 hours. Serum was stored at -20 ° C. Serum was analyzed for uric acid degrading activity as described in Example 5 and assayed for antibodies to uricase as described in Example 6.
    [63] Example 5
    [64] Assay of Uricate Activity of PEG-uricasees in Serum from Mice Injected with PEG-uricases
    [65] An activity assay based on ultraviolet light absorption (UV assay) was used as a substrate for a 100 μM uric acid in 200 mM sodium borate, pH 9.2, as a substrate . It was performed in microplate adaptation. Absorption at 292 nm for 15 minutes at room temperature in a 96-well plate with a UV-transparent bottom using a SpectraMAX 250 microplate reader from Molecular Devices (Sunnyvale, Calif.) The decrease in was monitored. This data was analyzed by finding the maximum slope (as milli-absorption units per minute) of absorbance measurements made during the interval during which the substrate was oxidized between 10 and 40%. The results obtained by this assay are shown in FIGS. 1 and 5.
    [66] The average half-life in the serum of mice initially injected with PKS uricase (6 × 10-kDa PEG PKS) bound to six strands of 10-kDa PEG per subunit was determined from serum obtained 24 and 72 hours after injection. Based on the data of, it was 29 ± 4 hours.
    [67] In separate experiments, detectable uric acid activity in mouse serum injected with PEG-uricase decreased during storage at −20 ° C., and maximum recovery of this activity was 4 h at 37 ° C., prior to assay. It was established that it is obtained by culturing. FIG. 5 shows the enzyme mono-Q as in Example 1, before recovery of uric acid activity after weekly repeated injections with 6 × 10-kDa PEG-PKS uricase was PEGylated according to the method of Example 3. Maximum when purified by column chromatography. The recovery was the highest after injection of the conjugate prepared from the high salt elution pool of Example 1 (see Figure 1), which had the minimum content of very large aggregates (the light scattering profile of fractions 7-10 in Figure 3). Purple). Moderate recovery was obtained by conjugates prepared from low salt elution pools from the mono Q column of Example 1, with the lowest recovery obtained by conjugates prepared from unfractionated PKS uricase. It has the highest content of large aggregates (see Figure 2). Whether using the UV assay described above or using an adapted colorimetric assay from P. Fossati et al. ( J. Clin. Chem (1980) 26: 227-231), serum assays were also performed. Irrespective of whether or not it was incubated at 37 ° C. before, the same sequence of recovered relative activity in serum after repeated injections (high salt pools> low salt pools> unfractionated uricase) was observed.
    [68] Example 6
    [69] Enzyme-linked immunosorbent assay (ELISA) of serum from mice injected with PEG-uricase
    [70] Noncompetitive ELISA analysis was performed on porcine uricase bound to 96-well Imulon 2 plates (Dynex Technologies, from VWR Scientific, San Francisco, Calif.). Primary antiserum was from mice injected with 6 × 10-kDa PEG conjugates or uricase prepared according to the method of Example 3. The second antibody was goat anti-mouse IgG bound to horseradish peroxidase (Calbiochem-Novabiochem # 401 253, La Jolla, Calif.) And the substrate was described in B. Porstmann et al. O-phenylenediamine dihydrochloride (Sigma P-9187, St. Louis, MO) as described by (J. Clin. Chem. Clin. Biochem. (1981) 19: 435-440).
    [71] 6 shows the results of a noncompetitive ELISA assay. The results showed that 6 × 10-kDa PEG-PKS uricase synthesized according to the method of Example 3 from the high salt eluate from the mono Q column of Example 1 (shown in FIG. 1) was injected weekly for 6 weeks. None of the eight mice produced a detectable immune response. Some mice injected with conjugates prepared from PKS uricase that were not fractionated according to the method of Example 3 showed a low but detectable immune response. The highest immune response occurred in mice injected with the conjugate prepared according to the method of Example 3 from the low salt elution pool from the mono Q column of Example 1.
    [72] As described in Example 2, without the benefit of the light scattering detector for size-exclusion HPLC analysis, the presence of the largest aggregates, not in the octameric form of ourcase, was observed in Example 5 (FIG. 5). Progressively reduced recovery of PEG-uricase conjugates after repeated injections, as well as) and accompanied by an increase in immunogenicity in BALB / c mice, as observed in Example 6 (Figure 6). It would not have been clear. These results have important implications for the specification of uricases used as starting materials for the preparation of PEG-uricasees for clinical use.
    [73] While the invention has been described in some detail by way of example for clarity of illustration and understanding, to those of ordinary skill in the art, without departing from the spirit and scope of the described and claimed, in view of the teachings of the invention, It will be apparent that any changes or modifications can be made there.
    权利要求:
    Claims (33)
    [1" claim-type="Currently amended] Purified uric acid oxidase (uricase) substantially free of aggregates larger than octamers.
    [2" claim-type="Currently amended] The uricase according to claim 1, wherein the uricase is a mammalian uricase.
    [3" claim-type="Currently amended] The uricase according to claim 2, wherein the uricase is swine liver, bovine liver or sheep liver uricase.
    [4" claim-type="Currently amended] The uricase according to claim 1, wherein the uricase is a recombinant.
    [5" claim-type="Currently amended] 5. The uricase according to claim 4, wherein the uricase has substantially the sequence of pig, bovine, sheep or bibial uricase.
    [6" claim-type="Currently amended] The uricase according to claim 4, wherein the uricase is chimeric.
    [7" claim-type="Currently amended] 7. The uricase according to claim 6, wherein the chimeric uricase comprises portions of porcine liver or non-liver liver uricase.
    [8" claim-type="Currently amended] 8. The uricase according to claim 7, wherein said chimeric uricase is PKS uricase.
    [9" claim-type="Currently amended] 5. The uricase according to claim 4, wherein the uricase has a sequence of non-liver liver uriase in which tyrosine No. 97 is substituted with histidine.
    [10" claim-type="Currently amended] 5. The uricase of claim 4, wherein the uricase comprises an amino terminus and a carboxy terminus, wherein the uricase is truncated at one or both termini.
    [11" claim-type="Currently amended] The uricase according to claim 1, wherein the uricase is a fungal or microbial uricase.
    [12" claim-type="Currently amended] 12. The method of claim 11, wherein the fungus or microbial uricase is Aspergillus flavus , Asrobacter globiformis, Bacillus sp. Or uricase , which is a recombinant enzyme isolated from Candida utility , or substantially having the sequence of one of the uriases.
    [13" claim-type="Currently amended] The uricase according to claim 1, wherein the uricase is an invertebrate uricase.
    [14" claim-type="Currently amended] The uricase according to claim 13, wherein the invertebrate uricase is a recombinant enzyme isolated from a drosophila melanogasster or a drosophila sudoprus , or substantially having a sequence of one of the uricases.
    [15" claim-type="Currently amended] The uricase according to claim 1, wherein the uricase is a plant uricase.
    [16" claim-type="Currently amended] 16. The method of claim 15 wherein the plant is Glycine Max, we claim Carr or separated from the root nodules of (Glycine max), or the us, we Carr recombinant enzyme having substantially the sequence of Carr claim.
    [17" claim-type="Currently amended] A conjugate of claim 1, which is conjugated to poly (ethylene glycol) or poly (ethylene oxide), wherein the uricase in the conjugate is substantially free of aggregates greater than octamers.
    [18" claim-type="Currently amended] 18. The uricase conjugate of claim 17, wherein the poly (ethylene glycol) is monomethoxy poly (ethylene glycol).
    [19" claim-type="Currently amended] 18. The uricase of claim 17, wherein the uricase is conjugated to a poly (ethylene glycol) or poly (ethylene oxide) via a bond selected from the group consisting of urethane (carbamate), secondary amines and amides. Conjugate.
    [20" claim-type="Currently amended] 18. The uricase conjugate of claim 17, wherein the poly (ethylene glycol) or poly (ethylene oxide) has a molecular weight between about 5 kDa and 30 kDa.
    [21" claim-type="Currently amended] The uricase conjugate of claim 20, wherein the poly (ethylene glycol) or poly (ethylene oxide) has a molecular weight between about 10 kDa and 20 kDa.
    [22" claim-type="Currently amended] 18. The uricase conjugate of claim 17, wherein the average number of strands of the poly (ethylene glycol) or poly (ethylene oxide) strand is between about 2 and 12 per uricase subunit.
    [23" claim-type="Currently amended] 23. The uricase conjugate of claim 22, wherein the average number of strands of said poly (ethylene glycol) or poly (ethylene oxide) strand is between about 6 and 10 per uricase subunit.
    [24" claim-type="Currently amended] 24. The uricase conjugate of claim 23, wherein the average number of strands of said poly (ethylene glycol) or poly (ethylene oxide) strand is between about 7 and 9 per uricase subunit.
    [25" claim-type="Currently amended] 18. The uricase conjugate of claim 17, wherein the poly (ethylene glycol) or poly (ethylene oxide) is linear.
    [26" claim-type="Currently amended] 18. The uricase conjugate of claim 17, wherein the poly (ethylene glycol) or poly (ethylene oxide) is branched.
    [27" claim-type="Currently amended] A pharmaceutical composition for lowering uric acid levels in a bodily fluid or tissue, comprising the conjugate of claim 17 and a pharmaceutically acceptable carrier.
    [28" claim-type="Currently amended] 28. The pharmaceutical composition of claim 27, wherein the composition is stabilized by freeze dehydration and dissolved by reconstitution to provide a suitable solution for parenteral administration.
    [29" claim-type="Currently amended] A method of purifying uricases with reduced immunogenicity comprising separating uricase aggregates larger than octamers in uricase fractions and excluding such aggregates from purified uricases.
    [30" claim-type="Currently amended] 30. The method of claim 29, wherein said separating step is selected from the group consisting of ion-exchange chromatography, size-exclusion chromatography, and ultrafiltration.
    [31" claim-type="Currently amended] 31. The method of claim 30, wherein said separating step comprises detecting aggregates greater than octamer in the uricase fractions and excluding the fractions containing the aggregates.
    [32" claim-type="Currently amended] 32. The method of claim 31, wherein said detecting step comprises a measurement of light scattering.
    [33" claim-type="Currently amended] An isolated uricase prepared by the method of claim 29.
    类似技术:
    公开号 | 公开日 | 专利标题
    JP6585643B2|2019-10-02|Macromolecule-Factor IX Conjugate
    US20190008978A1|2019-01-10|Conjugates of an il-2 moiety and a polymer
    EP2797622B1|2016-10-12|Ph20 polypeptide variants, formulations and uses thereof
    US20180250367A1|2018-09-06|Polymer-factor viii moiety conjugates
    ES2524598T3|2014-12-10|Polymeric Factor VIII Conjugates
    JP5334347B2|2013-11-06|Chemically modified novel erythropoietin stimulating protein compositions and methods
    US5438040A|1995-08-01|Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
    EP2049566B1|2009-12-30|G-csf site-specific mono-conjugates
    Pasut et al.2007|Polymer–drug conjugation, recent achievements and general strategies
    Kelly et al.2001|Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly |-modified uricase
    EP1885403B1|2013-05-08|Poly| conjugates of Lysostaphin
    US7201897B2|2007-04-10|Interferon conjugates
    US6913915B2|2005-07-05|PEG-modified uricase
    DK2459224T3|2016-07-25|Blodstørkningsproteinkonjugater
    Caliceti et al.1999|Biopharmaceutical properties of uricase conjugated to neutral and amphiphilic polymers
    Veronese et al.2008|The impact of PEGylation on biological therapies
    JP5687823B2|2015-03-25|Pharmaceutical products and their use for cancer treatment
    EP2535347A1|2012-12-19|Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
    EP0675727B1|2002-04-10|Glycolipid enzyme-polymer conjugates
    JP2005525302A|2005-08-25|Chemically modified human growth hormone conjugates
    EP2459226B1|2016-06-29|Glycopolysialylation of proteins other than blood coagulation proteins
    EP1278868B9|2008-10-29|Mutated form of arginine deiminase
    AU2004224466B2|2008-01-03|Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same
    AU2002255251B2|2007-10-11|Uses of chemically-modified cholinesterases for detoxification of organophosphorus compounds
    Tsui et al.2009|Pegylated derivatives of recombinant human arginase | for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell |
    同族专利:
    公开号 | 公开日
    ES2524153T3|2014-12-04|
    BE2013C045I2|2020-06-24|
    DK2196538T3|2015-01-05|
    TWI322184B|2010-03-21|
    MXPA02007545A|2002-12-13|
    HK1143989A1|2015-08-14|
    ZA200207206B|2003-05-06|
    BR0108386C1|2011-12-20|
    NZ520434A|2004-05-28|
    HK1144701A1|2014-06-06|
    ES2343105T8|2013-07-15|
    RU2557318C9|2015-09-10|
    RU2352354C2|2009-04-20|
    US20080057048A1|2008-03-06|
    ES2343105T3|2010-07-23|
    BR0108386B1|2017-10-31|
    BR0108386A|2002-10-29|
    EP2305819A1|2011-04-06|
    EP1254237A2|2002-11-06|
    HU0204544A3|2007-05-02|
    WO2001059078A3|2002-03-07|
    TW200914617A|2009-04-01|
    AT463576T|2010-04-15|
    HK1155203A1|2015-09-25|
    PT1254237E|2010-06-07|
    CA2398679C|2015-11-17|
    CN100491532C|2009-05-27|
    HU0204544A2|2003-05-28|
    US20110287466A1|2011-11-24|
    WO2001059078A2|2001-08-16|
    US7927852B2|2011-04-19|
    HK1056742A1|2009-11-27|
    CN101735991B|2013-09-11|
    RU2006107110A|2007-09-20|
    DK1254237T3|2010-07-19|
    IL193365A|2011-08-31|
    DK2305819T3|2015-01-05|
    PT2305819E|2015-06-01|
    AU4997501A|2001-08-20|
    JP5165826B2|2013-03-21|
    RU2557318C2|2015-07-20|
    DE60141742D1|2010-05-20|
    CN101735991A|2010-06-16|
    CZ304864B6|2014-12-17|
    IL151065D0|2003-04-10|
    AU2001249975B2|2006-06-08|
    PL358539A1|2004-08-09|
    RU2009104003A|2010-08-20|
    JP2003521937A|2003-07-22|
    AU2009212900B2|2011-12-08|
    CZ20022982A3|2003-01-15|
    LU92237I2|2013-09-03|
    EP2196538B1|2014-10-01|
    JP2011188861A|2011-09-29|
    IL151065A|2008-12-29|
    CY1110142T1|2015-01-14|
    PL208064B1|2011-03-31|
    EP2305819B1|2014-11-12|
    KR20080098686A|2008-11-11|
    US6783965B1|2004-08-31|
    KR20070092329A|2007-09-12|
    KR100884724B1|2009-02-19|
    AU2009212900A1|2009-10-01|
    CA2398679A1|2001-08-16|
    CY1117264T1|2017-04-26|
    HU227127B1|2010-07-28|
    KR101054247B1|2011-08-08|
    CN1423699A|2003-06-11|
    IL193365D0|2009-02-11|
    EP2196538A1|2010-06-16|
    EP1254237B1|2010-04-07|
    JP5341945B2|2013-11-13|
    RU2281954C2|2006-08-20|
    US8921064B2|2014-12-30|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2000-02-10|Priority to US09/501,730
    2000-02-10|Priority to US09/501,730
    2001-02-07|Application filed by 마운틴 뷰 파마슈티컬즈 인크.
    2002-11-23|Publication of KR20020087934A
    2009-02-19|Application granted
    2009-02-19|Publication of KR100884724B1
    优先权:
    申请号 | 申请日 | 专利标题
    US09/501,730|2000-02-10|
    US09/501,730|US6783965B1|2000-02-10|2000-02-10|Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates|
    [返回顶部]